Result: 5A), while V32I, V32C, and A71V showed large delays in the initial cleavage of Gag.
Result: For example, L10S had the lowest fitness score, but processed Gag faster than any other mutant variant while A71V had the highest fitness score among the mutant variants but showed a large delay in Gag cleavage.
Result: The largest increase in proficiency we observed was about 2-fold for Q92I cutting PR-RT and for A71V cutting TF-PR.
Result: Two of the mutations in this
Table: A71V
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Result: The most frequent mutations were L10I/V (32), A71I/T/V (28), and
Discussion: PI-associated mutations were found in 97 cases, most of which were secondary mutations like L10I/V, A71I/T/V, and K20I/R, so, there were relatively few cases of DR.
Discussion: In this study, among the PI-associated DR mutations detected, K20I/R and T74S were mainly found in CRF01_AE while A71I/T/V, Q58E, and V82I were frequently observed in CRF07_BC, indicating that the presence of different mutations may vary among different subtypes.
Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.
Introduction: Two mutations in PRS5B have a major association with drug-resistance (M46L and I84V), while nine are classified as minor drug resistance mutations (L10I, V11I, M36I, I54V, I62V, I63P, I64V, A71V, and G73T).
Result: Comparison of both PRS5B/PI structures with analogous wild-type complexes reveals how G73T and A71V mutations act in synergy with other accessory mutations to drive structural shifts of almost 3 A in Loop 2 in both subunits.
Result: Mutation A71V
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
PMID: 32556165
2020
The Journal of antimicrobial chemotherapy
Result: Only non-polymorphic and polymorphic PI accessory selected mutations were found in PT1 (K20T), PT4 (A71V) and PT5 (L10V).
Table: A71V
Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.
Introduction: Mutations at I50 are often selected together with
Result: A71V, a compensatory mutation that is far from the active site and almost always observed with I50V, restores the functionality to WT level (Km = 73 +- 9 muM), as previously reported.
Result: A time-course gel shift assay confirmed the catalytic activity of I50V single mutant, and the rescued activity of I50V/A71V variant in cleaving purified Gag polyprotein [Figure S1].
Discussion: A similar but distinct flap rearrangement was previously observed in response to a coevolution mutation in Gag substrate in the I50V/A71V variant, which enhances vdW interactions with the substrate.
HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases.
PMID: 30798679
2019
Journal of the International Association of Providers of AIDS Care
Conclusion: The HIV genotype at this time reported the RT gene mutations M184V and L100L/F, conferring resistance to emtricitabine and lamivudine, and protease gene mutations L10V, M36I/M, K43R, L63P, H69Y, A71A/V, and I93L.
Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam.
Introduction: One such example is the A71V mutation, a secondary mutation that, when observed in conjunction with I50V/L, acts to restore a balance between catalytic efficiency and inhibitor binding.
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
Discussion: In addition, A71V is also known as one of the common polymorphisms found in several percent PI-naive patients.
Discussion: In contrast, a set of data compiled for NDA21-976/S003 and NDA21-976/S004 clearly indicates that 10 amino acid substitutions including L10F, V32I, L33F, S37N, M46I, I47V
Discussion: It is interesting that when rHIVL33F/I84V was selected, this clone continued to propagate in the presence of increasing concentrations of DRV, acquired V32I (as examined at week 26) but without acquiring A71V, and became capable of propagating in the presence of 1 microM DRV by 26 weeks of selection.
HIV mutation literature information.
PMID: 
2021
Virus evolution
Browser Board
Co-occurred Entities
Filtrator
ViMRT